NCT02178592 - Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection | Biotech Hunter

Enrollment

113

Participants

Timeline

Start Date

January 23, 2015

Primary Completion Date

November 2, 2017

Study Completion Date

March 6, 2020

Conditions

Infection, Human Immunodeficiency VirusHIV Infections

Interventions

DRUG

DTG 50 mg

DTG is available as 50 mg film-coated tablet. DTG may be administered with or without food

DRUG

EFV 600 mg

EFV is supplied as film-coated capsule-shaped oral tablet containing 600 mg of EFV and must be administered without food

Trial Locations (28)

2013

GSK Investigational Site, Soweto

2092

GSK Investigational Site, Westdene

2574

GSK Investigational Site, Klerksdorp

4001

GSK Investigational Site, Durban

7505

GSK Investigational Site, Cape Town

7700

GSK Investigational Site, Cape Town

7925

GSK Investigational Site, Observatory, Cape Town

9301

GSK Investigational Site, Bloemfontein

10330

GSK Investigational Site, Bangkok

10400

GSK Investigational Site, Bangkok

14000

GSK Investigational Site, DF

40002

GSK Investigational Site, Khon Kaen

44160

GSK Investigational Site, Guadalajara

44280

GSK Investigational Site, Guadalajara

44340

GSK Investigational Site, Guadalajara

62290

GSK Investigational Site, Cuernavaca

194214

GSK Investigational Site, Saint Petersburg

302040

GSK Investigational Site, Oryol

C1202ABB

GSK Investigational Site, Ciudad de Buenos Aires

S2000PBJ

GSK Investigational Site, Rosario

69040-000

GSK Investigational Site, Manaus

40110-010

GSK Investigational Site, Salvador

21040-360

GSK Investigational Site, Rio de Janeiro

04121-000

GSK Investigational Site, São Paulo

Lima 32

GSK Investigational Site, San Miguel

Iqui 01

GSK Investigational Site, Iquitos

Lima 14

GSK Investigational Site, Lima

Lima 1

GSK Investigational Site, Lima